Future ValueIn 2018 MC had meetings promoting the impending rs. At one of those meeting he contended he wouldn't accept anything less than $1.5 billion. A lot has happened since the results seen from IND123 have mirrored; the panc trials have presented overly promising results; there is enough evidence in a variety of cnacers (MM, gastro-intestinal; glioma, etc.) to suggest the value now is far greater than the $1.5 billion MC preposed in 2018. As has been pointed out on this and other boards how can you get from less than $2 US or $$140 million market cap to somewhere near an acceptable market cap of $3 to $5 billion ( $50 to $70 sp)? This is definitely a leap and again as pointed out by contributors to the boards, highly unlikely. So can management and the board do what's required to get maximum value? It wouldn't surprise me if thesetype of discussions are occurring now. Realistically if you were a BP I don't believe there is a snowballs chance in hell they will even consider these lofty valuations with a current market cap of less than $140 million. This is a reflection of the managements ineffectiveness of getting the message out over the past 5 years. As they say "the hens have come home to roost".The next few months will be the most important for shareholders IMO.